Patricia Gauthier
Global Commercialization Lead, Rare Diseases and Latent Virus Moderna
- Boston MA UNITED STATES
Patricia Gauthier is actively involved in organizations that are committed to rethinking innovation and inspiring leadership.
Contact More Open optionsSocial
Biography
Patricia Gauthier joined Moderna at the end of 2020 as General Manager to set up and lead Moderna's Canadian organization. She played a key role in Moderna's response to the COVID-19 pandemic in Canada, and quickly established collaborative relationships with government and other life sciences stakeholders.
Before joining Moderna, Patricia spent 12 years at pharmaceutical giant GSK, holding key senior roles including Head of the Vaccines Business Unit and Head of Government Affairs and Market Access.
Patricia Gauthier's professional path has taken her to all corners of the world, living in the United States, Singapore and France, as well as London while working as a lawyer at McCarthy Tétrault. In addition to her legal studies, Patricia holds an MBA from HEC Montréal and certifications in strategic negotiation from Harvard Business School and in leadership from IMD.
Originally from Trois-Rivières, Patricia Gauthier has been based in Toronto for over a decade with her family. She is actively involved in organizations that are committed to rethinking innovation and inspiring leadership, like the Creative Destruction Lab, and from 2015-2019 she served as a board member of NEOMED, which fosters commercial opportunities for biotechnology innovations.
Industry Expertise
Areas of Expertise
Education
HEC Montréal
MBA
Université de Sherbrooke
LLB
Law
Multimedia
Accomplishments
CGCA - Business Achievement Award
2022
Links
Selected Media Appearances
We are updating the vaccine to target Omicron: President of Moderna Canada
Bloomberg tv
2023-11-03
Patricia Gauthier, president and general manager at Moderna Canada, joins BNN Bloomberg to discuss how the company's updated vaccine will offer broader protection and last longer.
MODERNA INITIATES ROLLING SUBMISSION TO HEALTH CANADA FOR UPDATED COVID-19 VACCINE
Yahoo! Finance online
2023-06-29
"As the COVID-19 virus evolves, so must the vaccines. An updated vaccine will ensure Canadians have the most current and effective option to keep them protected. We have initiated our submission with Health Canada and, pending approval, will be ready to supply an XBB monovalent vaccine in time for the fall," said Patricia Gauthier, President and General Manager, Moderna Canada.
Province announces $4M investment to bring mRNA vaccine production to Cambridge
CBC News online
2023-05-04
"Today is a very important milestone in that commitment," said president of Moderna Canada, Patricia Gauthier. "Moderna will now be able to deliver domestic ... mRNA vaccine production, ensuring Canadians have secure, on shore, direct access to our mRNA vaccines for future pandemic and health emergencies."
Talk by Patricia Gauthier, President and General Manager of Moderna Canada
The Chamber of Commerce of Metropolitan Montreal online
2022-12-05
Patricia Gauthier looked back at what she accomplished up to this point as the person responsible for bringing Moderna to Canada. In a short amount of time, the company went from being relatively unknown to Canadians to one that has big plans for Canada.
Moderna’s Patricia Gauthier is preparing Canada for the next pandemic
Maclean's online
2022-06-09
The company’s first Canadian general manager is laying the groundwork for the country to become a leader in vaccine production
Moderna is setting up a new office in Canada. The Star talked to its new Canadian head about plans for a new vaccine production facility, conspiracy theories and why mRNA vaccines work
Toronto Star online
2022-03-19
To call Patricia Gauthier’s introduction to Moderna Canada “intense” would be an understatement. After years at GSK Canada in government affairs and market access, pharma trade strategy and product management, she was tapped to be Moderna’s first hire in Canada.
Meet 50 emerging leaders reinventing how Canada does business
The Globe and Mail online
2022-02-25
On Nov. 30, 2020, U.S.-based pharmaceutical and biotech company Moderna completed Phase 3 clinical trials of its mRNA-1273 vaccine, announcing it was 94.1% effective against COVID-19. That same day, Patricia Gauthier became Moderna’s first—and, for two months, sole—Canadian hire.
Head of Moderna operations in Canada discusses COVID variants
CityNews tv
2021-07-20
Mel speaks with the general manager of Moderna operations in Canada, Patricia Gauthier, about how current vaccines will hold up against dangerous variants.
